A sulfur-containing relative of vitamin B5, taken apart within minutes of oral administration; the fragments appear to do the work. It shifts down the cholesterol that drives artery disease, and blood fats — largest where starting values were clearly abnormal. Stomach and bowel complaints are the main reported problem. Nothing tests whether it prevents heart attacks or extends life. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | 70–100 mg/dL | Primary target of the intervention |
| Apolipoprotein B | 60–80 mg/dL | Counts the artery-damaging particles directly |
| Triglycerides | 50–80 mg/dL | Most responsive lipid to pantethine |
| HDL cholesterol | 50–80 mg/dL | Tracks the inconsistent HDL response |
| Lipoprotein(a) | <75 nmol/L | Baseline risk not modified by pantethine |
| Alanine aminotransferase | 10–26 U/L (women), 10–30 U/L (men) | Liver safety and fatty-liver tracking |
| High-sensitivity C-reactive protein | <1.0 mg/L | Residual inflammatory risk alongside lipids |
| Platelet count | 175–250 × 10⁹/L | Baseline for the antiplatelet effect |
| Glycated hemoglobin | 4.8–5.4% | Confirms glucose control is unaffected |
Cadence: Lipids and apolipoprotein B at 8 weeks, again at 16 weeks, and thereafter every 6 to 12 months; liver enzymes and platelet count annually, or at 4 weeks in anyone taking an anticoagulant.